McDowell, Sheri A. C.
Luo, Robin B. E.
Arabzadeh, Azadeh
Doré, Samuel
Bennett, Nicolas C.
Breton, Valérie
Karimi, Elham
Rezanejad, Morteza
Yang, Ryan R.
Lach, Katherine D.
Issac, Marianne S. M. http://orcid.org/0000-0003-1113-9270
Samborska, Bozena
Perus, Lucas J. M.
Moldoveanu, Dan
Wei, Yuhong
Fiset, Benoit
Rayes, Roni F.
Watson, Ian R. http://orcid.org/0000-0002-6025-3080
Kazak, Lawrence http://orcid.org/0000-0002-7591-2544
Guiot, Marie-Christine
Fiset, Pierre O.
Spicer, Jonathan D. http://orcid.org/0000-0003-2708-1309
Dannenberg, Andrew J. http://orcid.org/0000-0002-1901-6497
Walsh, Logan A. http://orcid.org/0000-0001-8771-2577
Quail, Daniela F. http://orcid.org/0000-0002-6969-3250
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-19-034)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-162137, PJT-159742)
Canada Foundation for Innovation (JELF-39178, JELF-37488)
Susan G. Komen (CCR18548032)
Canada Foundation for Innovation
Article History
Received: 14 October 2019
Accepted: 10 March 2021
First Online: 3 May 2021
Competing interests
: P.O.F. has received honoraria and consultancy fees from Amgen Canada, AstraZeneca Canada, Bristol Myers Squibb, EMD Serono, Hoffmann-La Roche, Merck Canada, Pfizer Canada and Roche Canada. J.D.S. has received consultancy fees for BMS, Merck, Amgen, AstraZeneca, Protalix and TransHit Bio, and grant funding from AstraZeneca, CLS Therapeutics, Merck and Hoffman La Roche. All other authors declare no competing interests.
Free to read: This content has been made available to all.